Aug 09, 2023
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Jul 26, 2023
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
Jun 29, 2023
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
Jun 22, 2023
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
Jun 05, 2023
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
May 22, 2023
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 10, 2023
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 26, 2023
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
Apr 24, 2023
PolyPid to Participate in Upcoming Investor Conferences
Apr 14, 2023
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
Displaying 11 - 20 of 28